Skip to contentpdufa.bio

revumenib Publication

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

revumenib Publication is a Syndax Pharmaceuticals Inc program in R/R NUP98-rearranged acute leukemia. Its next catalyst is a Readout in Q4 2026.

SNDX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: R/R NUP98-rearranged acute leukemia. Sponsor: Syndax Pharmaceuticals Inc (SNDX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2026SNDX

Questions

When is revumenib Publication's next FDA decision or readout?

The next tracked catalyst for revumenib Publication is a Readout in Q4 2026.

What happened at revumenib Publication's most recent FDA decision?

No FDA decision for revumenib Publication is in our archive yet.

What is revumenib Publication used for?

In our records revumenib Publication is under review or in development for R/R NUP98-rearranged acute leukemia.

Who makes revumenib Publication?

Syndax Pharmaceuticals Inc (SNDX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.